INCB123667

DRUG6 trials

Sponsors

Incyte Corporation

Conditions

Healthy ParticipantsHepatic InsufficiencyLiver DiseasesOvarian CancerRenal Impairment

Phase 1

A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants

CompletedNCT06909162

Incyte CorporationHealthy Participants

Start: 2025-05-05End: 2026-05-17Updated: 2026-06-15

Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants

CompletedNCT07218744

Incyte CorporationHealthy Participants

Start: 2025-11-13End: 2025-12-10Updated: 2026-01-07

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

RecruitingNCT07559474

Incyte CorporationHepatic Insufficiency, Liver Diseases

Start: 2026-05-27End: 2027-04-13Target: 16Updated: 2026-06-16

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

RecruitingNCT07559396

Incyte CorporationRenal Impairment

Start: 2026-05-29End: 2027-01-04Target: 16Updated: 2026-06-16

Phase 2

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

RecruitingNCT07023627

Incyte CorporationOvarian Cancer

Start: 2025-11-12End: 2027-10-24Target: 160Updated: 2026-07-20

Phase 3

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

RecruitingNCT07214779

Incyte CorporationOvarian Cancer

Start: 2025-12-09End: 2029-05-14Target: 466Updated: 2026-07-20

Related Papers

A phase 3, randomized, open-label study of INCB123667 versus investigator's choice of chemotherapy in patients with platinum-resistant ovarian cancer with cyclin E1 overexpression (MAESTRA 2, ENGOT-OV95, GOG-3137).

Journal of Clinical Oncology2026-05-28